@article {PennellS46, author = {Nathan A. Pennell}, title = {Selection of chemotherapy for patients with advanced non{\textendash}small cell lung cancer}, volume = {79}, number = {5 e-suppl 1}, pages = {S46--S50}, year = {2012}, doi = {10.3949/ccjm.78.s2.10}, publisher = {Cleveland Clinic Journal of Medicine}, abstract = {Chemotherapy remains the first-line treatment for most patients with stage IV non{\textendash}small cell lung cancer (NSCLC), but optimal regimens are now defined by histology. Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. Maintenance therapy is emerging as a treatment strategy for patients who do not progress after four cycles of first-line chemotherapy. In the maintenance setting, pemetrexed and erlotinib significantly prolong overall survival compared with placebo after the completion of first-line chemotherapy.}, issn = {0891-1150}, URL = {https://www.ccjm.org/content/79/5_e-suppl_1/S46}, eprint = {https://www.ccjm.org/content/79/5_e-suppl_1/S46.full.pdf}, journal = {Cleveland Clinic Journal of Medicine} }